Eli Lilly and Company: Parkinson Disease trials
The registry lists 11 Parkinson Disease studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 5Phase 2 6Phase 3 1Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4006896 in Healthy Participants and Participants With Parkinson's DiseaseRecruitingNCT06809400Phase 1
- A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's DiseaseRecruitingNCT06565195Phase 1
- A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)CompletedNCT03305809Phase 2Results posted
- Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease PatientsCompletedNCT00857532Phase 2Results posted
- Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's DiseaseCompletedNCT00437125Phase 4Results posted
- Phase 2a Study of VTX3232 in Parkinson's DiseaseCompletedNCT06556173Phase 2
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruitingNCT04127578Phase 1/2
- A Study of LY3154207 in Healthy Participants and Participants With Parkinson's DiseaseCompletedNCT02562768Phase 1
- A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement DisordersCompletedNCT01550484Phase 2/3
- A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)CompletedNCT01503944Phase 1/2
- Observational Study of Pergolide Mesylate and Cardiac ValvulopathyCompletedNCT00311532